Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page annual report packed with optical genome mapping jargon can stall even seasoned analysts. Bionano Genomics annual report 10-K simplified is more than a paperwork chore—it's the key to understanding how instrument placements drive consumable pull-through and how R&D spending shapes future cash needs. If you've ever wished Bionano Genomics SEC filings explained simply, you're not alone.
Stock Titan’s AI decodes every disclosure in real time. Need the latest Bionano Genomics quarterly earnings report 10-Q filing or a concise Bionano Genomics 8-K material events explained summary? Our platform delivers both, plus side-by-side Bionano Genomics earnings report filing analysis that highlights segment revenue shifts and gross-margin trends. Interactive dashboards turn understanding Bionano Genomics SEC documents with AI into a two-minute task—no more line-item treasure hunts.
Curious whether insiders are buying Saphyr’s promise? Track Bionano Genomics insider trading Form 4 transactions with instant alerts. Our feed captures Bionano Genomics Form 4 insider transactions real-time, flags sizable Bionano Genomics executive stock transactions Form 4, and links them back to the proxy for context on Bionano Genomics proxy statement executive compensation. From patent milestones in 8-Ks to dilution risks disclosed in 10-Qs, Stock Titan surfaces what moves the stock—so you can act on data, not dense prose.
Bionano Genomics (NASDAQ: BNGO) has filed an 8-K/A to amend its previous filing from June 13, 2025, correcting voting results for two key proposals. The amendment specifically addresses errors in reporting Broker Non-Votes and Votes For on Proposals 3 and 4.
Key Corrections:
- Proposal 3 (Ratification of BDO USA as auditor): Corrected to show 0 Broker Non-Votes instead of previously reported 769,744
- Proposal 4 (Warrant Exercise Share Issuance): Updated to show 396,176 Votes For (previously 369,176) and 769,744 Broker Non-Votes (previously unreported)
The corrections do not affect the outcome of either vote. Proposal 4 approved the issuance of up to 661,374 shares of common stock related to warrant exercises from a January 3, 2025 securities purchase agreement with institutional investors, in compliance with Nasdaq Listing Rule 5635(d).
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
What is the primary focus of Bionano Genomics Inc?
How does the company generate its revenue?
Which industries benefit from Bionano's technologies?
How does Bionano differentiate itself from traditional genomic analysis methods?
What regions does Bionano operate in?
Who are the typical customers of Bionano Genomics?
Why is optical genome mapping important in genomic research?
Does Bionano offer any software solutions with its hardware products?
